CC
NTLA icon

Casdin Capital’s Intellia Therapeutics NTLA Stock Holding History

Casdin Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$1.38M – 40
2024
Q1 		$1.38M Buy
+50,000
New +$1.39M 0.1% 34

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Casdin Capital's NTLA Position: Q1 2026 in Review

Casdin Capital opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 355,000 shares worth $4.55M. The stake represents 0.34% of the portfolio and ranks #28 among its holdings. This is a return to the name: Casdin Capital previously reported a position in NTLA as recently as Q1 2025.

Casdin Capital first reported a position in NTLA in Q3 2022 and has held it in 12 quarters since. The position peaked at $52M in Q2 2023. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Casdin Capital held 355,000 shares of Intellia Therapeutics worth $4.55M as of Q1 2026.
  • Intellia Therapeutics was a new Casdin Capital position in Q1 2026.
  • Intellia Therapeutics made up 0.34% of Casdin Capital's portfolio in Q1 2026, its #28 holding.
  • Casdin Capital first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Casdin Capital's Intellia Therapeutics position peaked at $52M in Q2 2023.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.